Published in Neuroreport on July 13, 2005
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 1.05
B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol (2009) 1.01
Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells. Cell Commun Signal (2015) 0.99
PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther (2016) 0.98
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport (2009) 0.90
Immune Evasion Strategies of Glioblastoma. Front Surg (2016) 0.88
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget (2016) 0.82
Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neurosci (2010) 0.81
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep (2016) 0.81
Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. J Vis Exp (2015) 0.80
Antibody-based immunotherapy for malignant glioma. Semin Oncol (2014) 0.80
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. Front Oncol (2015) 0.79
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J Control Release (2016) 0.76
Targeting immune checkpoints in malignant glioma. Oncotarget (2016) 0.75
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol (2017) 0.75
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol (2002) 4.50
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol (2012) 2.56
EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res (2008) 2.39
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res (2003) 2.15
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92
Retracted Marker-independent identification of glioma-initiating cells. Nat Methods (2010) 1.84
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol (2012) 1.74
Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity (2005) 1.74
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med (2007) 1.64
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol (2010) 1.44
Initial cord blood unit volume affects mononuclear cell and CD34+ cell-processing efficiency in a non-linear fashion. Cytotherapy (2011) 1.43
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 1.40
IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One (2008) 1.38
Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature. BMC Infect Dis (2006) 1.33
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol (2005) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol (2004) 1.29
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med (2002) 1.25
Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res (2007) 1.22
Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interv Radiol (2005) 1.21
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol (2013) 1.15
Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer (2009) 1.14
A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol (2006) 1.13
Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells. J Cell Physiol (2004) 1.13
Percutaneous CT-guided multisampling core needle biopsy of thoracic lesions. AJR Am J Roentgenol (2005) 1.12
Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol (2002) 1.11
Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. J Immunother (2005) 1.10
Giant plexiform neurofibroma in neurofibromatosis type 1. Arch Neurol (2010) 1.09
Imaging of the larynx and hypopharynx. Eur J Radiol (2008) 1.09
Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol (2007) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res (2010) 1.07
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica (2012) 1.05
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res (2002) 1.03
Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother (2013) 1.02
Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One (2013) 0.99
All in the head: obstacles for immune rejection of brain tumours. Immunology (2002) 0.99
Dedifferentiated laryngeal chondrosarcoma: combined morphologic and functional imaging with positron-emission tomography/magnetic resonance imaging. Laryngoscope (2013) 0.97
Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response. Int J Cancer (2014) 0.94
Direct transoral approach to C2 for percutaneous vertebroplasty. Cardiovasc Intervent Radiol (2002) 0.93
Acute streptococcal myopericarditis mimicking myocardial infarction. Am J Emerg Med (2008) 0.92
Percutaneous vertebroplasty in metastatic disease: transpedicular access and treatment of lysed pedicles--initial experience. Radiology (2003) 0.91
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One (2009) 0.91
Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol (2004) 0.91
Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol (2003) 0.90
In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol (2008) 0.89
Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol (2011) 0.89
TNF-alpha induces the generation of Langerin/(CD207)+ immature Langerhans-type dendritic cells from both CD14-CD1a and CD14+CD1a- precursors derived from CD34+ cord blood cells. Eur J Immunol (2003) 0.89
Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity. Cell Transplant (2010) 0.89
Cytomegalovirus colitis--a severe complication after standard chemotherapy. Acta Oncol (2002) 0.88
Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts. J Leukoc Biol (2013) 0.87
Primary clear-cell chondrosarcoma of the cervical spine. Case illustration. J Neurosurg Spine (2006) 0.86
Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J Virol (2004) 0.86
Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol (2004) 0.86
Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma. Glia (2010) 0.86
Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol (2003) 0.86
Death receptors on reactive astrocytes: a key role in the fine tuning of brain inflammation? Neurology (2003) 0.84
Fulminant Lewy body disease. Mov Disord (2006) 0.84
Management of malignant pleural effusion and ascites by a triple access multi perforated large diameter catheter port system. World J Surg Oncol (2008) 0.84
Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. PLoS One (2013) 0.84
Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature. Acta Neuropathol (2003) 0.83
Getting by with a little help from the right CD4(+) T cells. Oncoimmunology (2013) 0.83
Human CD34+ CD11b- cord blood stem cells generate in vitro a CD34- CD11b+ subset that is enriched in langerin+ Langerhans dendritic cell precursors. Exp Hematol (2006) 0.83
Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol (2006) 0.82
Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues. J Immunol (2004) 0.82
Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics (2014) 0.82
Physical activity promotion among oncology nurses. Cancer Nurs (2012) 0.82
Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol (2006) 0.81
Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol (2012) 0.81
Radicular pain after vertebroplasty: compression or irritation of the nerve root? Initial experience with the "cooling system". Spine (Phila Pa 1976) (2003) 0.81
A self-defence mechanism of astrocytes against Fas-mediated death involving interleukin-8 and CXCR2. Neuroreport (2002) 0.81
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity. J Neuroinflammation (2013) 0.81
Radiolucent lesions of the mandible: a pattern-based approach to diagnosis. Insights Imaging (2013) 0.81
A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist (2012) 0.81
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther (2002) 0.81
Intrathecal MTX for DLBCL: from an inappropriate prophylactic tradition to a medical error? Blood (2009) 0.80
Plasmablastic lymphoma clinically presenting in the urinary tract. Ann Diagn Pathol (2011) 0.80
T-cell immunotherapy for malignant glioma: toward a combined approach. Curr Opin Oncol (2010) 0.80
Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. Support Care Cancer (2007) 0.80